Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.

Melatonin is a hormone in the brain that maintains your body's circadian rhythm, and therefore, regulates sleep. Taking ...

Some patients with atopic dermatitis who qualify for advanced systemic therapies do not receive them or may lack improvement with these therapies.

Ocular surface disease symptoms in individuals with comorbid atopic dermatitis are more common and severe, and self-rated vision is worse.

Panelists discuss how ruxolitinib cream demonstrated significant clinical efficacy in treating atopic dermatitis over a 12-month period, with claims analysis revealing improved disease control, ...

The "Enterprise Tech Ecosystem Series: Almirall - 2025" company profile has been added to ResearchAndMarkets.com's offering. The report provides insights into the Almirall's tech activities, including ...

Background: Atopic dermatitis (AD) significantly impacts both the physical and psychological well-being of children and caregivers. As AD severity increases, so does its negative effect on the ...

Corvus Pharmaceuticals suffered lately, especially after it announced in December 2024 its early AD data. Check out why I ...

Corvus Pharmaceuticals has faced volatility due to mixed clinical data and given the current valuation and market ...

Dupilumab treatment of atopic dermatitis resulted in long-term skin improvements linked to changes in skin’s the molecular composition.